Kirk Campbell, MD
- PROFESSOR | Medicine, Nephrology
Kirk Campbell, MD, is Professor of Medicine, Vice Chair for Diversity, Equity and Inclusion and Director of the Nephrology Fellowship Program. He is board certified in Nephrology.
Dr. Campbell is a graduate of the University of Connecticut School of Medicine and completed residency training in Internal Medicine at Yale-New Haven Hospital followed by a clinical and research fellowship in Nephrology at Mount Sinai. In addition to treating patients with kidney disease, Dr. Campbell leads an NIH-funded research program focused on developing new therapeutic interventions for proteinuric diseases. He actively participates in clinical trials testing novel agents for primary glomerular disease and is an elected member of the American Society for Clinical Investigation.
He is a Past-President of the New York Society of Nephrology, a member of the Board of Directors of the Nephcure Foundation, a standing member of the Pathobiology of Kidney Disease (PBKD) study section at the National Institutes of Health, the Medical Advisory Board of the National Kidney Foundation of Greater New York. He has served on the American Society of Nephrology Grants Review and Kidney Week Education Committees.
Multi-Disciplinary Training AreaPharmacology and Therapeutics Discovery [PTD]
MD, University of Connecticut
Residency, Internal Medicine, Yale-New Haven Hospital
Fellowship, Nephrology, Mount Sinai Hospital
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure. Primary and secondary pathogenic processes affecting podocytes account for 90% of end-stage kidney disease at a cost of 20 billion dollars per year in the US. A reduction in podocyte number (podocytopenia) directly correlates with the progression of several proteinuric kidney diseases including focal segmental glomerulosclerosis (FSGS), IgA nephropathy and diabetic nephropathy. Despite significant advances in the characterization of the molecular architecture of podocytes, the mechanisms underlying their survival, injury and loss remain poorly understood. Validated therapeutic targets are scarce and there are currently no podocyte-specific drugs commercially available. The overall goal of our research program is to enhance the pipeline of putative therapeutic targets available to tackle human glomerular disease by elucidating the details and functional significance of key signaling pathways that regulate podocyte injury and survival. We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression. Please go to The Campbell Laboratory.